Cost-Effectiveness of Fidaxomicin for Clostridium difficile Treatment

被引：2
|
作者：
Simon, Matthew S. [1 ,2 ]
机构：
[1] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA
[2] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10065 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2014年 / 58卷 / 04期
关键词：
VANCOMYCIN; INFECTION; CANCER;
D O I：
10.1093/cid/cit772
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting
    Lam, Simon W.
    Neuner, Elizabeth A.
    Fraser, Thomas G.
    Delgado, David
    Chalfin, Donald B.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2018, 39 (08) : 924 - 930
  • [32] Fidaxomicin: New therapy for Clostridium difficile-associated diarrhea
    Grant, Edward M.
    FORMULARY, 2011, 46 (08) : 297 - +
  • [33] Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection
    Venugopal, Anilrudh A.
    Johnson, Stuart
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (04) : 568 - 574
  • [34] Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis
    Konijeti, Gauree G.
    Sauk, Jenny
    Shrime, Mark G.
    Gupta, Meera
    Ananthakrishnan, Ashwin N.
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (11) : 1507 - 1514
  • [35] Fidaxomicin and Fecal Microbiota Transplants for Severe Clostridium difficile Colitis
    Mankal, Pavan Kumar
    Abed, Jean
    Latte-Naor, Shelly
    Grinspan, Ari
    Kotler, Donald P.
    AMERICAN JOURNAL OF THERAPEUTICS, 2019, 26 (01) : E115 - E117
  • [36] Fidaxomicin for the treatment of Clostridioides difficile in children
    Skinner, Andrew M.
    Scardina, Tonya
    Kociolek, Larry K.
    FUTURE MICROBIOLOGY, 2020, 15 (11) : 967 - 979
  • [37] SINGLE CENTRE CLINICAL EXPERIENCE WITH FIDAXOMICIN IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN SLOVAKIA
    Novotny, Martin
    Jarcuska, Pavol
    Gombosova, Laura
    Hockicko, Jan
    Hockickova, Ivana
    Rovnakova, Alena
    Zahornacky, Ondrej
    Schreter, Ivan
    Dorko, Erik
    Rimarova, Kvetoslava
    CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, 2018, 26 : S76 - S80
  • [38] Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin
    Biswas, J. S.
    Patel, A.
    Otter, J. A.
    Wade, P.
    Newsholme, W.
    van Kleef, E.
    Goldenberg, S. D.
    JOURNAL OF HOSPITAL INFECTION, 2015, 90 (03) : 267 - 270
  • [39] Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection
    Hvas, Christian Lodberg
    Jorgensen, Simon Mark Dahl
    Jorgensen, Soren Peter
    Storgaard, Merete
    Lemming, Lars
    Hansen, Mette Mejlby
    Erikstrup, Christian
    Dahlerup, Jens Frederik
    GASTROENTEROLOGY, 2019, 156 (05) : 1324 - +
  • [40] Fidaxomicin: A guide to its use in Clostridium difficile infection
    Scott L.J.
    Drugs & Therapy Perspectives, 2014, 30 (3) : 85 - 91
12345